Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology
  • Published:

Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases

British Journal of Cancer volume 78, pages 1058–1060 (1998)Cite this article

Abstract

Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK

    C Fordy

Authors
  1. C Fordy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MM Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. TG Allen-Mersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fordy, C., Glover, C., Davies, M. et al. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer 78, 1058–1060 (1998). https://doi.org/10.1038/bjc.1998.627

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1998.627

Search

Advanced search

Quick links